



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Cwm Taf Morgannwg
University Health Board



Freedom of Information Request: Our Reference CTMUHB_449_25

You asked:

1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:
 - Adalimumab - Humira
 - Adalimumab Biosimilar
 - Etrasimod
 - Filgotinib
 - Golimumab
 - Infliximab - Remicade
 - Infliximab Biosimilar
 - Mirikizumab
 - Ozanimod
 - Risankizumab
 - Tofacitinib
 - Upadacitinib
 - Ustekinumab - Stelara
 - Ustekinumab Biosimilar
 - Vedolizumab

Our response:

Please find below a table populated with the information Medicines Management are able to provide at this current time. The period the data relates to 1st July 2025 to 30th September 2025 the latest 3 months available as requested.

Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

Medicine	Number of Patients
Adalimumab - Humira	**
Adalimumab Biosimilar	227
Etrasimod	0
Filgotinib	**
Golimumab	0
Infliximab - Remicade	**
Infliximab Biosimilar	263
Mirikizumab	0
Ozanimod	0
Risankizumab	40
Tofacitinib	**
Upadacitinib	52
Ustekinumab - Stelara	10
Ustekinumab Biosimilar	186
Vedolizumab	234